The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project

Launched by THE UNIVERSITY OF HONG KONG · Jan 30, 2020

Keywords

ClinConnect Summary

The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project is a clinical trial aimed at understanding a type of blood cancer called Acute Promyelocytic Leukemia (APL). The study seeks to gather important information about how common APL is in Asia, how it behaves, and how well different treatments work, especially comparing a new oral treatment called oral arsenic trioxide (oral-As2O3) with other existing treatments. Researchers believe that by collecting data from various countries in Asia, they can improve treatment options for patients with APL.

To participate in this trial, individuals must be 18 years or older and have a confirmed diagnosis of APL, which includes a specific genetic marker known as PML/RARA. The trial is open to all genders. Participants can expect to share their treatment experiences, which will help researchers learn more about the best ways to treat APL. This study is currently recruiting, which means they are looking for volunteers to join. Your involvement could contribute to better care for future patients with this condition.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Patients aged 18 or above
• • Acute promyelocytic leukaemia with PML/RARA
• • Acute myeloid leukaemia with variant RARA translocation
• Exclusion criteria:
• • -Acute myeloid leukaemia without PML/RARA or variant RARA translocation